Relay Therapeutics (RLAY) Revenue & Revenue Breakdown
Relay Therapeutics Revenue Highlights
Latest Revenue (Y)
$25.55M
Relay Therapeutics Revenue by Period
Relay Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $25.55M | 1749.82% |
| 2022-12-31 | $1.38M | -54.41% |
| 2021-12-31 | $3.03M | -96.34% |
| 2020-12-31 | $82.65M | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | - |
Relay Therapeutics generated $25.55M in revenue during NA 2023, up 1749.82% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Relay Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | -100.00% |
| 2024-03-31 | $10.01M | -1000800.00% |
| 2023-12-31 | $-1.00K | -100.00% |
| 2023-09-30 | $25.20M | 21078.15% |
| 2023-06-30 | $119.00K | -47.35% |
| 2023-03-31 | $226.00K | -10.67% |
| 2022-12-31 | $253.00K | -26.45% |
| 2022-09-30 | $344.00K | -5.75% |
| 2022-06-30 | $365.00K | -12.89% |
| 2022-03-31 | $419.00K | -26.10% |
| 2021-12-31 | $567.00K | -14.86% |
| 2021-09-30 | $666.00K | -21.09% |
| 2021-06-30 | $844.00K | -11.34% |
| 2021-03-31 | $952.00K | -98.85% |
| 2020-12-31 | $82.65M | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | - |
Relay Therapeutics generated - in revenue during Q2 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Relay Therapeutics Revenue Breakdown
Relay Therapeutics Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Sep 22 | Jun 22 | Mar 22 |
|---|---|---|---|
| License | $300.00K | $300.00K | $200.00K |
Latest
Relay Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Sep 22: License (100.00%).
Relay Therapeutics Revenue Breakdown by Country
Quarterly Revenue by Country
| Country | Sep 22 | Jun 22 | Mar 22 |
|---|---|---|---|
| License | $300.00K | $300.00K | $200.00K |
Latest
Relay Therapeutics's latest quarterly revenue breakdown by geography, as of Sep 22: License (100.00%).
Relay Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals | $380.79M | $416.00K |
| APLS | Apellis Pharmaceuticals | $366.28M | $176.57M |
| BPMC | Blueprint Medicines | $249.38M | $128.18M |
| ARVN | Arvinas | $78.50M | $102.40M |
| NRIX | Nurix Therapeutics | $76.99M | $12.59M |
| FHTX | Foghorn Therapeutics | $34.16M | $7.81M |
| RLAY | Relay Therapeutics | $25.55M | - |
| STOK | Stoke Therapeutics | $8.78M | $4.89M |
| IPSC | Century Therapeutics | $2.23M | $791.00K |
| PLRX | Pliant Therapeutics | $1.58M | - |
| LIFE | aTyr Pharma | $353.00K | $235.00K |
| CGEM | Cullinan Oncology | - | - |
| BDTX | Black Diamond Therapeutics | - | - |
| CCCC | C4 Therapeutics | - | - |
| DAWN | Day One Biopharmaceuticals | - | $20.07M |
| TERN | Terns Pharmaceuticals | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| EWTX | Edgewise Therapeutics | - | - |